Emerging drugs for Parkinson's disease

John Christopher Morgan, Kapil D. Sethi

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Parkinson's disease (PD) afflicts millions of people worldwide. There are numerous drugs available for PD; however, levodopa remains the gold standard of pharmacotherapy to which all other therapies are compared. Levodopa is quite effective for many motor symptoms (bradykinesia, tremor, rigidity) of PD; however, non-levodopa-responsive motor symptoms (postural instability) and nonmotor symptoms are frequently the most troublesome in middle and later stages of disease. Although motor symptoms remain an important focus for emerging drugs, current research is largely geared to identify and develop disease-slowing therapies. Another important area of focus has become treatment of the nonmotor symptoms of PD (especially depression and dementia). This review discusses emerging drugs in the management of the motor and nonmotor symptoms of PD and drugs under study as disease-slowing/neuroprotective agents.

Original languageEnglish (US)
Pages (from-to)403-417
Number of pages15
JournalExpert Opinion on Emerging Drugs
Volume11
Issue number3
DOIs
StatePublished - Sep 1 2006

Fingerprint

Parkinson Disease
Pharmaceutical Preparations
Levodopa
Hypokinesia
Neuroprotective Agents
Tremor
Dementia
Therapeutics
Depression
Drug Therapy
Research

Keywords

  • ACP-103
  • Coenzyme Q
  • Creatine
  • Dementia
  • Depression
  • Donepezil
  • Dopamine agonist
  • Dyskinesias
  • Galantamine
  • GDNF
  • Glutamic acid decarboxylase
  • GPI-1485
  • MAO-B inhibitor
  • Memantine
  • Minocycline
  • Modafinil
  • Nefazodone
  • Neuroprotection
  • Neurturin
  • Paroxetine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Emerging drugs for Parkinson's disease. / Morgan, John Christopher; Sethi, Kapil D.

In: Expert Opinion on Emerging Drugs, Vol. 11, No. 3, 01.09.2006, p. 403-417.

Research output: Contribution to journalReview article

Morgan, John Christopher ; Sethi, Kapil D. / Emerging drugs for Parkinson's disease. In: Expert Opinion on Emerging Drugs. 2006 ; Vol. 11, No. 3. pp. 403-417.
@article{45d9b01cfb1740139d8810dbe11268f4,
title = "Emerging drugs for Parkinson's disease",
abstract = "Parkinson's disease (PD) afflicts millions of people worldwide. There are numerous drugs available for PD; however, levodopa remains the gold standard of pharmacotherapy to which all other therapies are compared. Levodopa is quite effective for many motor symptoms (bradykinesia, tremor, rigidity) of PD; however, non-levodopa-responsive motor symptoms (postural instability) and nonmotor symptoms are frequently the most troublesome in middle and later stages of disease. Although motor symptoms remain an important focus for emerging drugs, current research is largely geared to identify and develop disease-slowing therapies. Another important area of focus has become treatment of the nonmotor symptoms of PD (especially depression and dementia). This review discusses emerging drugs in the management of the motor and nonmotor symptoms of PD and drugs under study as disease-slowing/neuroprotective agents.",
keywords = "ACP-103, Coenzyme Q, Creatine, Dementia, Depression, Donepezil, Dopamine agonist, Dyskinesias, Galantamine, GDNF, Glutamic acid decarboxylase, GPI-1485, MAO-B inhibitor, Memantine, Minocycline, Modafinil, Nefazodone, Neuroprotection, Neurturin, Paroxetine",
author = "Morgan, {John Christopher} and Sethi, {Kapil D.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1517/14728214.11.3.403",
language = "English (US)",
volume = "11",
pages = "403--417",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Emerging drugs for Parkinson's disease

AU - Morgan, John Christopher

AU - Sethi, Kapil D.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Parkinson's disease (PD) afflicts millions of people worldwide. There are numerous drugs available for PD; however, levodopa remains the gold standard of pharmacotherapy to which all other therapies are compared. Levodopa is quite effective for many motor symptoms (bradykinesia, tremor, rigidity) of PD; however, non-levodopa-responsive motor symptoms (postural instability) and nonmotor symptoms are frequently the most troublesome in middle and later stages of disease. Although motor symptoms remain an important focus for emerging drugs, current research is largely geared to identify and develop disease-slowing therapies. Another important area of focus has become treatment of the nonmotor symptoms of PD (especially depression and dementia). This review discusses emerging drugs in the management of the motor and nonmotor symptoms of PD and drugs under study as disease-slowing/neuroprotective agents.

AB - Parkinson's disease (PD) afflicts millions of people worldwide. There are numerous drugs available for PD; however, levodopa remains the gold standard of pharmacotherapy to which all other therapies are compared. Levodopa is quite effective for many motor symptoms (bradykinesia, tremor, rigidity) of PD; however, non-levodopa-responsive motor symptoms (postural instability) and nonmotor symptoms are frequently the most troublesome in middle and later stages of disease. Although motor symptoms remain an important focus for emerging drugs, current research is largely geared to identify and develop disease-slowing therapies. Another important area of focus has become treatment of the nonmotor symptoms of PD (especially depression and dementia). This review discusses emerging drugs in the management of the motor and nonmotor symptoms of PD and drugs under study as disease-slowing/neuroprotective agents.

KW - ACP-103

KW - Coenzyme Q

KW - Creatine

KW - Dementia

KW - Depression

KW - Donepezil

KW - Dopamine agonist

KW - Dyskinesias

KW - Galantamine

KW - GDNF

KW - Glutamic acid decarboxylase

KW - GPI-1485

KW - MAO-B inhibitor

KW - Memantine

KW - Minocycline

KW - Modafinil

KW - Nefazodone

KW - Neuroprotection

KW - Neurturin

KW - Paroxetine

UR - http://www.scopus.com/inward/record.url?scp=33748665990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748665990&partnerID=8YFLogxK

U2 - 10.1517/14728214.11.3.403

DO - 10.1517/14728214.11.3.403

M3 - Review article

C2 - 16939381

AN - SCOPUS:33748665990

VL - 11

SP - 403

EP - 417

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -